secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001213900-25-100156
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M
-------------------------------------------------------------------------------

- Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.
- FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.
- Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.
- Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.
- Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/0001213900-25-100156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea0261760-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-100156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer